Optimizing delivery of next generation immune potentiators
Dr Manmohan Singh, Novartis Vaccines, North Carolina, USA

DNA Vaccination Encoding CD40 Targeted to Dendritic Cells Protects Against Chronic Kidney Disease.
Dr Yuan Min Wang, Senior Scientist, Senior Lecturer, University of Sydney Renal Laboratory, Centre for Kidney Research, Australia

Tubular immunostimulating complex based on glycolipid and saponin from marine hydrobiont
Professor Nina Sanina, Far Eastern Federal University, Russia

Virus Related Cancer In Immunosuppressed Individuals
Dr Diego Serraino, MD, Epidemiology and Biostatistics Unit – National Cancer Institute, Italy

Talk title to be confirmed
Dr Isabelle Heard, Pasteur Institute, Hopital Pitie-Salpetrière, France

Talk title to be confirmed
Dr Sanjay Bhagani, Consultant Physician and honorary Senior Lecturer, Royal Free London Foundation Trust, UK

Talk to be confirmed
Professor Yvonne Perrie, Aston University, Birmingham, UK

Talk to be confirmed
Professor Talin Barisani-Asenbauer, Scientific Director, OCUVAC – Centre of Ocular Inflammation and Infection, Medical University of Vienna, Austria

Pseudotypes versus traditional Virus Neutralization, advantage and future perspectives:
Professor Emanuele Montomoli; MSc, MBiochem; Dept. of Molecular and Developmental Medicine, University of Siena, Via Aldo Moro 3, 53100, Siena, Italy

Development of Dissolvable Microneedle Patches for Skin-based Immunization
Dr Anne Moore, School of Pharmacy, Dept. of Pharmacology & Therapeutics, University College Cork, Ireland

Modular, adaptable Nanoparticle-based vaccines and applications:
Dr Tarek Fahmy, PHD, Associate Professor of Biomedical and Chemical Engineering, Associate Professor of Immunobiology, Yale University, New Haven, CT, USA

SMARTer Vaccines: Next-Generation Vaccinia Virus Vaccine and Therapeutic Vectors:
Assistant Professor Paulo H. Verardi, Ph.D., Institutional Biosafety Committee (IBC) Chairperson, University of Connecticut, Dept of Pathobiology & Vet Science, Storrs, CT, USA

Angiotensin and Systems Thinking, Wrapping your mind around the big picture:
Dr Gary R Smith, Perses Biosystems Limited, University of Warwick Science Park, Coventry, UK

Improving the cellular immune response obtainable by adenovirus vectored vaccines
Associate Professor Peter J. Holst, MD, PhD., University of Copenhagen, CSS, Department of International Health, Immunology and Microbiology, Øster Farigmagsgade 5, Copenhagen, Denmark

Hazard Group 4 Agents: Wild, Tamed & In Disguise
Dr. Kevin S. Richards, Senior Molecular Virologist, High Containment Microbiology Department, PHE Porton, Porton Down, Salisbury, Wiltshire, UK

Protein nanoparticles with built-in adjuvant properties
Professor Peter Burkhard, PhD, Department of Molecular and Cell Biology, The Institute of Materials Science, University of Connecticut, CT, USA

The combined effects of genetic background  and mannose-binding lectin ligands on the response to an avian coronavirus vaccination
Dr Rikke Munkholm Kjærup, Dept. of Animal Science, Aarhus University, Blichers Allé 20, Postboks 50, DK-8830 Tjele, Denmark

Adeno-Associated viral (AAV) pseudotyping as a tool for gene therapy and genetic vaccine applications
Dr Takis Athanasopoulos, Ph.D, Lecturer in Molecular Biotechnology, Faculty of Science and Engineering, University of Wolverhampton, City Campus South, Wulfruna St., Wolverhampton, WV1 1LY, UK

Competition: Issues in the Distribution of the Health Care Workforce in Administering Vaccines
Professor Donald B. Giddon, AB, MA, DMD, PhD, Clinical Professor of Developmental Biology, Faculty of Medicine, Harvard University, Wellesley, MA, USA

Stable HIV-based pseudotype particles and sugar antigen display on retroviral pseudotype particles
Dr Yasu Takeuchi, 1.3.11, Wohl Virion Centre, Cruciform Building, Gower Street, London WC1E  6BT, UK

Evaluation of a pseudotyped lentivirus-based neutralisation assay for potency testing of rabies immunoglobulins
Dr Giada Mattiuzzo, The National Institute for Biological Standards and Control, The Medicines and Healthcare Products Regulatory Agency, Blanche Lane, South Mimms, Potters Bar, U.K.

Immunomodulation through lipopeptide structure-activity relationships for the development of a synthetic self-adjuvanting Group A streptococcus vaccine candidate
Dr Mehfuz Zaman PhD, NHMRC Early career fellow, Institute for Glycomics, Griffith university, Parklands Drive, Southport, Australia